{
    "nct_id": "NCT04659564",
    "official_title": "Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study",
    "inclusion_criteria": "* Males and females â‰¥ 18 years of age\n* Willing to sign the informed consent and deemed capable of following the study protocol\n* Subjects must have a diagnosis of primary or secondary unilateral or bilateral upper extremity edema\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Individuals with a history or presence of a systemic disorder or condition that could place the patient at increased risk from sequential compression therapy\n* Inability or unwillingness to participate in all aspects of study protocol and/or inability to provide informed consent\n* Patients with exam results that would prevent safe and effective use of the study device (cellulitis, open-wounds, healing-wounds, etc.)\n* Diagnosis of active or recurrent cancer, or less than 3 months at the time of initial evaluation from the completion of chemotherapy, radiation therapy or primary surgery for the treatment of cancer\n* Diagnosis of Acute infection (in the last two weeks)\n* Diagnosis of acute thrombophlebitis (in last 2 months)\n* Diagnosis of peripheral arterial disease (PAD): PAD is defined as an Ankle Brachial Index (ABI), of 0.7 or lower\n* Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months\n* Diagnosis of pulmonary edema\n* Diagnosis of congestive heart failure (uncontrolled)\n* Diagnosis of chronic kidney disease\n* Diagnosis of epilepsy\n* Patients with poorly controlled asthma\n* Any condition where increased venous and lymphatic return is undesirable\n* Women who are pregnant, planning a pregnancy or nursing at study entry\n* Participation in any clinical trial of an investigational substance or device during the past 30 days",
    "miscellaneous_criteria": ""
}